Home›Trial›NCT07095465
NCT07095465Phase 3ENROLLING BY INVITATION

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

Study Summary

A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Conditions
Lewy Body Dementia Psychosis
Interventions / Drugs
ACP-204
View on ClinicalTrials.gov ↗
Sponsor
ACAD
ACADIA Pharmaceuticals
Neuroscience
B77/100
Study Details
Enrollment126 participants
Primary Completion—
Lead SponsorACADIA Pharmaceuticals Inc.
Data Retrieved2026-04-11 02:52:05.277027+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 126 participants
Sponsor Catalyst Profile

ACADIA Pharmaceuticals (ACAD) is the sponsoring company for this trial. BiotechSign currently grades this company B (77/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ACAD Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.